@article{yi_newman_zhang_johansson_sannes_2015, title={Heparin and LPS-induced COX-2 expression in airway cells: a link between its anti-inflammatory effects and GAG sulfation}, volume={41}, ISSN={["1521-0499"]}, DOI={10.3109/01902148.2015.1091053}, abstractNote={ABSTRACT Purpose/Aim: Previous studies have indicated that the sulfated polysaccharide heparin has anti-inflammatory effects. However, the mechanistic basis for these effects has not been fully elucidated. Materials and Methods: NCI-H292 (mucoepidermoid) and HBE-1 (normal) human bronchial epithelial cells were treated with LPS alone or in the presence of high-molecular-weight (HMW) fully sulfated heparin or desulfated HMW heparin. Cells were harvested to examine the phosphorylation levels of ERK1/2, p38, and NF-kB p65 and COX-2 protein expression by Western blot and gene expression of both COX-2 and CXCL-8 by TaqMan qRT-PCR. Results: Heparin is known to exert an influence on receptor-mediated signaling through its ability to both potentiate and inhibit the receptor-ligand interaction, depending upon its concentration. In H292 cells, fully-sulfated HMW heparin significantly reduced LPS-induced gene expression of both COX-2 and CXCL-8 for up to 48 hours, while desulfated heparin had little to no significant suppressive effect on signaling or on COX-2 gene or protein expression. Desulfated heparin, initially ineffective at preventing LPS-induced CXCL8 up-regulation, reduced CXCL8 transcription at 24 hours. In contrast, in normal HBE-1 cells, fully sulfated heparin significantly suppressed only ERK signaling, COX-2 gene expression at 12 hours, and CXCL-8 gene expression at 6 and 12 hours, while desulfated heparin had no significant effects on LPS-stimulated signaling or on gene or protein expression. Sulfation determines heparin's influence and may reflect the moderating role of GAG sulfation in lung injury and health. Conclusions: Heparin's anti-inflammatory effects result from its nonspecific suppression of signaling and gene expression and are determined by its sulfation.}, number={9}, journal={EXPERIMENTAL LUNG RESEARCH}, author={Yi, Na Young and Newman, Donna R. and Zhang, Huiying and Johansson, Helena Morales and Sannes, Philip L.}, year={2015}, month={Oct}, pages={499–513} }
 @article{davis_yi_salmon_charlton_colitz_gilger_2012, title={Sustained-Release Celecoxib from Incubated Acrylic Intraocular Lenses Suppresses Lens Epithelial Cell Growth in an Ex Vivo Model of Posterior Capsule Opacity}, volume={28}, ISSN={["1080-7683"]}, DOI={10.1089/jop.2011.0196}, abstractNote={PURPOSE
To determine whether celecoxib (CXB) can be released from incubated intraocular lenses (IOLs) sufficiently to inhibit lens epithelial cell (LEC) growth in an ex vivo model of posterior capsule opacification (PCO).


MATERIALS
LEC growth was evaluated for 14 days in canine lens capsules (LCs) that had been exposed to media containing 20 μM CXB for 1-5 days. After the incubation of hydrophilic and hydrophobic IOLs in CXB solution, the determination of the in vitro release of CXB from the IOLs was performed for up to 28 days. The incubated and nonincubated IOLs were evaluated in the ex vivo model of PCO, and the rate of LEC growth was evaluated over 28 days.


RESULTS
The treatment of LCs with 20 μM CXB for 4 and 5 days completely inhibited LEC growth. LEC repopulation did not occur after the removal of CXB. IOLs incubated in CXB for 24 h resulted in a sustained release of CXB in vitro at levels theoretically sufficient to inhibit PCO. LCs in the ex vivo model of PCO treated with acrylic IOLs incubated in CXB had significantly suppressed LEC ingrowth compared with untreated and IOL-only LCs.


CONCLUSIONS
A 4-day treatment of LCs with a concentration of 20 μM CXB may effectively prevent PCO. IOLs incubated in CXB for 24 h resulted in a sustained release of CXB in vitro at levels sufficient to inhibit LEC growth in the ex vivo model of PCO. Further studies are needed to determine whether CXB-incubated IOLs can effectively prevent the development of PCO in vivo.}, number={4}, journal={JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS}, author={Davis, Jennifer L. and Yi, Na Young and Salmon, Jacklyn H. and Charlton, Anna N. and Colitz, Carmen M. H. and Gilger, Brian C.}, year={2012}, month={Aug}, pages={359–368} }
 @article{yi_park_jeong_kim_kim_kim_chae_jang_seong_seo_2009, title={Comparison of orbital prosthesis motility following enucleation or evisceration with sclerotomy with or without a motility coupling post in dogs}, volume={12}, ISSN={["1463-5224"]}, DOI={10.1111/j.1463-5224.2009.00691.x}, abstractNote={Abstract}, number={3}, journal={VETERINARY OPHTHALMOLOGY}, author={Yi, Na Young and Park, Shin Ae and Jeong, Man Bok and Kim, Won Tae and Kim, Se Eun and Kim, Ji Youn and Chae, Je Min and Jang, Kyoung Jin and Seong, Je Kyung and Seo, Kang Moon}, year={2009}, pages={139–151} }
 @article{douglas_yi_davis_salmon_gilger_2008, title={Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses}, volume={31}, ISSN={0140-7783 1365-2885}, url={http://dx.doi.org/10.1111/j.1365-2885.2008.00986.x}, DOI={10.1111/j.1365-2885.2008.00986.x}, abstractNote={ In vitro photosensitivity of rapamycin (RAPA) and ocular toxicity and distribution of intravitreal and subconjunctival RAPA was evaluated in normal horses. RAPA (2.5 mg, 5 mg, and 10 mg) was placed in 10 mL of PBS and maintained in a water bath at 37 °C, kept in the dark or subjected to room light, and sampled for up to 3 months for RAPA levels. Six normal adult horses received either 5 mg (n = 2) or 10 mg (n = 2) of RAPA intravitreally or 10 mg (n = 2) subconjunctivally. Ophthalmic exams and electroretinography (ERG) were performed prior to injection and on days 1, 7, 14, and 21 post‐injection. Eyes were enucleated and samples were collected for RAPA concentrations and histopathology. No difference in light vs. dark RAPA concentrations was observed, suggesting a lack of RAPA phototoxicity. No evidence of ocular toxicity was noted on ophthalmic examination or histopathology. RAPA was not detected intraocularly 7 days post‐injection in eyes receiving subconjunctival RAPA, but was detected in the vitreous at 21 days post‐injection. Drug could be detected in both the aqueous and vitreous humor after intravitreal injection. Further study is needed to determine the efficacy of intravitreal RAPA.}, number={6}, journal={Journal of Veterinary Pharmacology and Therapeutics}, publisher={Wiley}, author={Douglas, L. C. and Yi, N. Y. and Davis, J. L. and Salmon, J. H. and Gilger, B. C.}, year={2008}, month={Dec}, pages={511–516} }
 @article{gilger_salmon_yi_barden_chandler_wendt_colitz_2008, title={Role of bacteria in the pathogenesis of recurrent uveitis in horses from the southeastern United States}, volume={69}, ISSN={0002-9645}, url={http://dx.doi.org/10.2460/ajvr.69.10.1329}, DOI={10.2460/ajvr.69.10.1329}, abstractNote={Abstract}, number={10}, journal={American Journal of Veterinary Research}, publisher={American Veterinary Medical Association (AVMA)}, author={Gilger, Brian C. and Salmon, Jacklyn H. and Yi, Na Y. and Barden, Curtis A. and Chandler, Heather L. and Wendt, Jennifer A. and Colitz, Carmen M. H.}, year={2008}, month={Oct}, pages={1329–1335} }